1 |
CV30 |
Human IgG |
Infected COVID-19 patients |
6XE1 |
D420-Y421, Y453, L455-N460, Y473-S477, F486-N487, Y489, Q493, T500, G502, Y505 |
Block hACE2-RBD interaction |
no |
IC50 value of 0.03 µg/mL |
[35] |
2 |
REGN10933 Recombinant |
full-human antibodies |
Humanized mice and COVID-19-convalescent patients |
6XDG |
R403, K417, Y421, Y453, L455-F456, A475-G476, E484-Y489, Q493 |
Block hACE2-RBD interaction, ADCC & ADCP |
no |
IC50 value of 37.4 pM |
|
3 |
B38 |
Human IgG |
COVID-19-convalescent patient |
7BZ5 |
R403, D405-E406, Q409, D420-Y421, Y452, L454-N460, Y473-S477, F486-N487, Y489-F490, Q493-G496, Q498, T500-V503, Y505 |
Block hACE2-RBD interaction |
no |
A single dose of B38 (25 mg/kg) |
[35] |
4 |
CC12.1 |
Human IgG |
COVID-19-convalescent patient |
6XC3 |
R403, D405-E406, R408-Q409, D420-Y421, Y453, L455-N460, Y473-S477, F486-N487, Y489, Q493-G496, Q498, T500-V503, Y505 |
Block hACE2-RBD interaction |
no |
IC50 value of 0.019 µg/mL |
[36] |
5 |
CB6 |
Human IgG |
COVID-19-convalescent patient |
7C01 |
R403, D405-E406, R408-Q409, D420-Y421, L455-N460, Y473-S477, F486-N487, Y489, Q493, Y495, N501-G502, G504-Y505 |
Block hACE2-RBD interaction |
no |
A single dose of CB6-LALA (50 mg/kg) |
[37] |
6 |
C105 |
Human IgG |
COVID-19-convalescent patient |
6XCN, 6XCM |
R403, D405, R408, D420-Y421, Y453, L455-N460, Y473, A475-G476, F486-N487, G502, Y505 |
Block hACE2-RBD interaction |
no |
IC50 value of 26.1 ng/mL |
[41] |
7 |
CC12.3 |
Human IgG |
COVID-19-convalescent patient |
6XC7 |
R403, D405, D420-Y421, Y453, L455-N460, Y473-S477, F486-N487, Y489, Q493, G496, N501, Y505 |
Block hACE2-RBD interaction |
no |
IC50 value of 0.018 µg/mL |
[42] |
8 |
CR3022 |
Human IgG |
SARS-convalescent patient |
6YOR, 6 W41 |
Y369-N370, F374-K386, L390, F392, D428, T430, F515-L517 |
Trapping RBD in the less stable up conformation while leading to destabilization of S |
SARS-CoV, SARS-CoV-2 |
ND50 value of 0.114 µg/mL |
[19] |
9 |
EY6A |
Human IgG |
Late-stage COVID-19 patient |
6ZDH, 6ZER, 6ZCZ |
Y369, F374-S375, F377-K386, N388, L390, P412-G413, D427-F429, L517 |
destabilization of S |
SARS-CoV, SARS-CoV-2 |
ND50 value of ~10.8 µg/mL |
[26] |
10 |
VHH-72 |
Llama single domain antibody |
llama immunized with prefusionstabilized betacoronavirus spikes |
6WAQ |
Y356-T359, F361-C366, A371-T372, G391-D392, R395, N424, I489, Y494 |
Trapping RBD in the less stable up conformation while leading to destabilization of S, Block hACE2_RBD interaction |
SARS-CoV, SARS-Co-V-2 |
IC50 values of 0.14 µg/mL and 0.2 mg/mL. |
[19] |
11 |
BD23 |
Human IgG |
COVID-19-convalescent patient |
7BYR |
G446, Y449, L452, T470, E484-F486, Y489-F490, L492-S494, G496, Q498, T500-N501, Y505 |
Block hACE-RBD2 interaction |
no |
IC50 value of 8.5 µg/mL |
[26] |
12 |
Fab 2–4 |
Human IgG |
Infected COVID-19 patients |
6XEY |
Y449, Y453, L455-F456, E484-F486, Y489-F490, L492-S494, G496 |
Locking RBD in the down conformation while occluding access to ACE2 |
no |
Neutralizing SARS-CoV-2 live virus with IC50 value of 0.057 µg/mL |
[41] |